-Advertisement-
-Advertisement-
Cataract/Anterior Segment

ImprimisRx Announces Supply Agreement with iOR Partners

Posted on March 9, 2020
Oyster Point Pharma announces collaboration with Adaptive Phage Therapeutics (APT) to target ophthalmic diseases

ImprimisRx, an ophthalmic-focused outsourcing facility and pharmaceutical compounding business, has agreed to a product supply agreement with iOR Partners, a company dedicated to office-based cataract surgery suites.

ImprimisRx will provide a variety of formulations needed for in-office surgeries including injectables and topical products.

Read the full press release here.

-Advertisement-
Related Articles
How do patients use social media after cataract surgery?
Jul 29, 2021
Cataract surgery reduces average number ocular hypotensive medications
Jul 22, 2021
American Academy of Ophthalmology and ASCRS Urge Aetna to Reverse Disruptive New Policy on Cataract Surgery
Jul 05, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-